Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 20/20 | 1.00 |
| ▸ | F7 | P08709 | 18/20 | 1.00 |
| ▸ | F10 | P00742 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3538346 | 0.93 | F11 (1.00) | F11F7F10 | |
| SCHEMBL3540262 | 0.92 | F11 (1.00) | F11F7F10 | |
| SCHEMBL4734566 | 0.92 | F11 (0.85) | F11F7F10 | |
| SCHEMBL3542381 | 0.91 | F11 (1.00) | F11F7F10 | |
| SCHEMBL3541174 | 0.90 | F11 (1.00) | F11F7F10 | |
| SCHEMBL3548300 | 0.90 | F11 (1.00) | F11F7F10 | |
| SCHEMBL3537798 | 0.90 | F11 (1.00) | F11F7F10 | |
| SCHEMBL3536283 | 0.89 | F11 (1.00) | F11F7F10 | |
| SCHEMBL3539683 | 0.89 | F11 (1.00) | F11F7F10 | |
| SCHEMBL3548918 | 0.88 | F11 (0.92) | F11F7F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | claimed |
| EP-1601656-A4 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-11 | — | — | EP | claimed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | claimed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | claimed |
| US-7138412-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | claimed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| EP-1601656-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | claimed |
| WO-2004080971-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-23 | — | — | WO | claimed |
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-7709646-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| US-7138412-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060223854-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | QUAN MIMI L | 2006-10-05 | — | — | US | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | F11 3907/4885F7 4325/4885F10 4435/4885 |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | TFPI, F2, TFPI2 | F11 7/4885F7 23/4885F10 18/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | F11 3552/4885F7 4234/4885F10 4360/4885 |
| US-20060223854-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | F12, F2, TFPI | F11 9/4885F7 20/4885F10 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.